Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA.
Hypertension. 2012 Mar;59(3):740-6. doi: 10.1161/HYPERTENSIONAHA.111.181735. Epub 2012 Feb 6.
Imbalances in circulating angiogenic factors contribute to the pathogenesis of preeclampsia. To characterize levels of angiogenic factors in pregnant women with chronic hypertension, we prospectively followed 109 women and measured soluble fms-like tyrosine kinase 1 (sFlt1), soluble endoglin, and placental growth factor at 12, 20, 28, and 36 weeks' gestation and postpartum. Superimposed preeclampsia developed in 37 (34%) and was early onset (<34 weeks) in 9 and later onset (≥34 weeks) in 28. Circulating levels of sFlt1 and the ratio of sFlt1 to placental growth factor were higher before clinical diagnosis at 20 weeks' gestation in women who subsequently developed early onset preeclampsia between 28 and 34 weeks compared with levels in women who never developed preeclampsia (P=0.001) or who developed late-onset preeclampsia (P=0.001). Circulating levels of sFlt1, soluble endoglin, and the ratio of sFlt1:placental growth factor were also significantly higher, and placental growth factor levels were significantly lower at the time of clinical diagnosis of superimposed preeclampsia in women with either early or late-onset superimposed preeclampsia compared with levels at similar gestational ages in those with uncomplicated chronic hypertension. We conclude that alterations in angiogenic factors are detectable before and at the time of clinical diagnosis of early onset superimposed preeclampsia, whereas alterations were observed only at the time of diagnosis in women with late-onset superimposed preeclampsia. Longitudinal measurements of angiogenic factors may help anticipate early onset superimposed preeclampsia and facilitate diagnosis of superimposed preeclampsia in women with chronic hypertension.
循环血管生成因子失衡导致子痫前期的发病机制。为了描述慢性高血压孕妇的血管生成因子水平,我们前瞻性地随访了 109 名孕妇,并在 12、20、28 和 36 周妊娠和产后测量了可溶性 fms 样酪氨酸激酶 1(sFlt1)、可溶性内皮因子和胎盘生长因子。37 例(34%)发生重叠性子痫前期,9 例为早发性(<34 周),28 例为晚发性(≥34 周)。与从未发生子痫前期的孕妇(P=0.001)或发生晚发性子痫前期的孕妇(P=0.001)相比,在 20 周妊娠时,随后在 28 至 34 周之间发生早发性子痫前期的孕妇,sFlt1 和 sFlt1 与胎盘生长因子比值在临床诊断前的循环水平较高。在发生早发性或晚发性重叠性子痫前期的孕妇中,sFlt1、可溶性内皮因子和 sFlt1:胎盘生长因子比值在临床诊断时也显著升高,而胎盘生长因子水平在妊娠相似年龄时显著降低。我们的结论是,在早发性重叠性子痫前期的临床诊断之前和之时,血管生成因子的改变是可以检测到的,而在晚发性重叠性子痫前期的孕妇中,仅在诊断时观察到这些改变。血管生成因子的纵向测量可能有助于预测早发性重叠性子痫前期,并有助于诊断慢性高血压孕妇的重叠性子痫前期。